Skip to main content

NantHealth Signs Distribution Deal for GPS Cancer in Southeast Asia

NEW YORK (GenomeWeb) – NantHealth announced today that it has signed a distribution agreement for its cancer molecular profiling service GPS Cancer with Asia Genomics.

Under the terms of the deal, Asia Genomics will distribute GPS Cancer to physicians in Singapore, Malaysia, Thailand, Vietnam, and the Philippines. Additional terms of the agreement were not disclosed.

GPS Cancer integrates whole-genome sequencing, whole-transcriptome sequencing, and quantitative proteomics to provide oncologists with a molecular profile of a patient's specific cancer.

"While cancer incidences continue to increase worldwide, GPS cancer is leading the evolution from a one-size-fits-all treatment approach to the era of proteogenomics and quantitative proteomics," NantHealth Founder and CEO Patrick Soon-Shiong said in a statement. "Through the exclusive partnership with Asia Genomics, GPS cancer is offered for the first time in Southeast Asia. This is an important step in the global expansion of GPS cancer and we're excited to be bringing a much-needed alternative to transform the way that cancer is treated in this region."